Novavax’s COVID vaccine gets FDA approval
Digest more
The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.
US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus on seniors, high-risk persons.
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk.
Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to adults over 65 and people who are high risk. The move is a significant shift
The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face